3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
6
Withdrawn
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
2
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Conditions
Lymphoma, Follicular
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
lutetium Lu 177 dotatate
15
Magnetic Resonance Spectroscopy
9
Everolimus
8
gallium Ga 68 dotatate
6
lanreotide
4
cabozantinib
4
Temozolomide
4
Specimen Handling
4
Nivolumab
4
Lutetium-177
4
Lutetium
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
surufatinib
3
olaparib
3
copper dotatate CU-64
3
Somatostatin
3
Injections
3
Ga(III)-DOTATOC
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Capecitabine
3
pembrolizumab
2
fludarabine phosphate
2
fludarabine
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Sunitinib
2
Radiosurgery
2
Octreotide
2
Drug Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
pasireotide
×
NET
×
Clear all
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled